Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5340450 | 0.80 | POLB (0.46) | CASP3CA12CA9MEN1KMT2A | |
| SCHEMBL7484938 | 0.80 | DRD3 (0.41) | CASP3CA12CA9MEN1KMT2A | |
| SCHEMBL613586 | 0.80 | DRD3 (0.44) | CASP3CA12CA9MEN1KMT2A | |
| SCHEMBL900640 | 0.77 | DRD3 (0.46) | CASP3CA12CA9CA1CA2 | |
| SCHEMBL4632890 | 0.74 | ALDH1A1 (0.49) | CASP3CA12CA9CA1CA2 | |
| SCHEMBL10871583 | 0.74 | DRD3 (0.44) | CA12CA9ALDH1A1DRD3ALDH2 | |
| SCHEMBL8059312 | 0.73 | DRD3 (0.39) | CASP3ALDH1A1DRD3GAA | |
| SCHEMBL5069988 | 0.73 | NR1H2 (0.44) | CA12CA9MEN1KMT2AALDH1A1 | |
| SCHEMBL6302393 | 0.72 | CASP3 (0.43) | CASP3CA12CA9MEN1KMT2A | |
| SCHEMBL7491735 | 0.72 | ADRA1D (0.53) | ALDH1A1ALDH3A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| EP-1631569-A2 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | Novartis AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004096800-A2 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | CASP3 3673/4885CA12 1074/4885CA9 1135/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | CASP3 3673/4885CA12 1074/4885CA9 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.